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The quest to develop a vaccine against HIV represents a major effort in viral immunology, but has 
met with limited success.  While there are naturally occurring antibodies, such as 4E10, that 
neutralize a wide range of HIV strains, they occur in few patients and have not been elicited through 
any standard vaccine development approach.  To determine why 4E10 is difficult to generate 
through standard vaccine development regimes, graduate student Kathryn Finton and colleagues in 
the laboratory of Dr. Roland Strong (Basic Sciences Division) traced its path to maturity by 
determining the structure of 4E10 alone and in complex with part of its target, the HIV Env protein, 
as well as the structures of several of its mostly likely germline-encoded precursors (GEPs).  This 
analysis showed that mature 4E10 gained both host reactivity and structural flexibility, but lost 
stability.  These findings run counter to expectations of standard vaccination protocols, which 
assume reduced host reactivity and structural stability upon maturation.  "These results help show 
why it's so difficult to develop an HIV vaccine: not only does HIV do everything conceivable to evade 
immune responses, but the uncommon antibodies that do slip through the virus's defenses may 
have properties that make them inherently exceedingly difficult to generate through vaccination," 
said Dr. Strong. 
The researchers first identified a group of candidate GEPs for 4E10.  As they did not have access to 
the donor from which 4E10 was derived, the precursors were predicted using known features of 
DNA sequence rearrangements leading to antibody diversity.  This analysis led to an ensemble of 
eight GEPs chosen for further study.  These GEPs, each encoding a variable antigen-recognition 
region (Fv), were then expressed in bacteria.  All but one GEP Fv displayed proper folding and, 
notably, higher thermal stability than 4E10 Fv.  However, GEP Fvs showed very weak HIV 
neutralization when compared to 4E10. 
To determine changes in HIV-binding properties during the maturation of 4E10, the authors analyzed 
the binding of 4E10 and GEP Fvs to HIV Env proteins.  GEP Fvs displayed unquantifiable but 
detectable weak binding to Env proteins, and a 100- to 10,000-fold reduction in affinity for 
engineered antigens relative to 4E10 Fv.  Structural comparisons of 4E10 and GEP Fvs bound to the 
engineered substrate T117 revealed a high degree of binding site conservation, suggesting that the 
increased affinity of 4E10 for T117 is influenced by indirect effects outside of the antigen binding 
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site.  Further structural analysis showed that T117 makes extensive contacts with 4E10 outside of 
the targeted epitope, potentially explaining the increased affinity of 4E10 for this molecule. 
The authors assessed the polyspecificity (that is, the ability of an antibody to specifically recognize 
multiple antigens) and the autoreactivity of 4E10 and GEPs using a library of over 400,000 36-amino 
acid peptides.  Both 4E10 and GEP Fvs displayed similar degrees of polyspecificity, though their 
profiles of autoreactivity varied.  This is a striking and counterintuitive result result, as a decrease in 
polyspecificity is part of the consensus model of antibody maturation. 
This study shows that the highly HIV-reactive 4E10 antibody developed through a pathway distinct 
from that of the current paradigm.  The results suggest that 4E10 is unlikely to be elicited through 
conventional vaccination strategies and thus highlights the need for understanding of unconventional 
antibody maturation pathways. 
Finton KAK, Friend D, Jaffe J, Gewe M, Holmes MA, Larman HB, Stuart A, Larimore K, Greenberg 
PD, Elledge SJ, Stamatatos L, Strong RK. 2014. Ontogeny of Recognition Specificity and 
Functionality for the Broadly Neutralizing Anti-HIV Antibody 4E10.  PLOS Pathog 10(9): e1004403. 
 
Image provided by Dr. Roland Strong 
Structures of the antigen-recognition portion of 4E10 (left) and 
one of its antecedents (right) bound to the targeted peptide of 
the HIV Env protein (grey corkscrews). 
